Acurx Pharmaceuticals, Inc.
ACXP
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.88% | -18.97% | -28.21% | -30.54% | -31.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.82% | -35.97% | -42.69% | -43.63% | -39.83% |
| Operating Income | 23.82% | 35.97% | 42.69% | 43.63% | 39.83% |
| Income Before Tax | 24.93% | 36.85% | 43.51% | 44.21% | 40.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.93% | 36.85% | 43.51% | 44.21% | 40.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.93% | 36.85% | 43.51% | 44.21% | 40.23% |
| EBIT | 23.82% | 35.97% | 42.69% | 43.63% | 39.83% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.20% | 68.35% | 66.00% | 60.64% | 53.29% |
| Normalized Basic EPS | 71.20% | 68.35% | 66.00% | 60.64% | 53.29% |
| EPS Diluted | 71.20% | 68.35% | 66.00% | 60.64% | 53.29% |
| Normalized Diluted EPS | 71.20% | 68.35% | 66.00% | 60.64% | 53.29% |
| Average Basic Shares Outstanding | 179.29% | 122.77% | 85.37% | 51.69% | 32.67% |
| Average Diluted Shares Outstanding | 179.29% | 122.77% | 85.37% | 51.69% | 32.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |